For the mRNA platform vaccines, as of November 21, 2022, the respective doses of BNT162b2 or mRNA 1273 administered have been: U.S., 387M, and 255 M; Japan, 255 M and 80 M; EU, 653 M and 153M. 63 ...

We have proposed new amino acid secondary structure propensities in proteins with different folding types based on synonymous codons. They have been derived from 200 all alpha, all beta, alpha/beta, ...

To overcome the inherent challenge of translation termination interference caused by stop codon reprogramming in mammalian ...

To overcome the inherent challenge of translation termination interference caused by stop codon reprogramming in mammalian ...

To overcome the inherent challenge of translation termination interference caused by stop codon reprogramming in mammalian ...

The US Food and Drug Administration has approved new labeling for two mRNA COVID-19 vaccines (Comirnaty; Pfizer and Spikevax; Moderna) that emphasizes the risk of myocarditis and pericarditis. The ...

On June 24, 2025, Cambridge Healthcare Innovations (CHI), a start-up developing inhaler technology, announced that its dry powder inhaler (DPI) engine, Quattrii, is the first of its kind to deliver ...

Post pandemic, Moderna Inc. is broadening the applications of mRNA technology to cancer, rare diseases, latent viruses and respiratory viruses, “taking advantage” of the revenue generated by Spikevax ...

Frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17) is caused by the aberrant alternative pre-mRNA splicing of microtubule-associated protein tau (MAPT) exon 10, the inclusion ...

Researchers develop a self-regulating mRNA medicine that adjusts protein production based on disease-related signals. A research team from The University of Osaka and Institute of Science Tokyo ...